SG10201510586PA - Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy - Google Patents
Treatment of Eye Diseases And Excessive Neovascularization Using A Combined TherapyInfo
- Publication number
- SG10201510586PA SG10201510586PA SG10201510586PA SG10201510586PA SG10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- eye diseases
- combined therapy
- excessive neovascularization
- neovascularization
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13360708P | 2008-06-30 | 2008-06-30 | |
AU2008903349A AU2008903349A0 (en) | 2008-06-30 | Treatment of eye diseases and excessive neovascularization using combined therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201510586PA true SG10201510586PA (en) | 2016-01-28 |
Family
ID=41507350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201510586PA SG10201510586PA (en) | 2008-06-30 | 2009-06-29 | Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy |
Country Status (9)
Country | Link |
---|---|
US (1) | US20110200612A1 (en) |
EP (1) | EP2294184A4 (en) |
JP (2) | JP2011526892A (en) |
KR (1) | KR20110036101A (en) |
CN (1) | CN102076844B (en) |
AU (2) | AU2009269149B2 (en) |
CA (1) | CA2729303A1 (en) |
SG (1) | SG10201510586PA (en) |
WO (1) | WO2010005527A1 (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013003594A2 (en) * | 2011-06-28 | 2013-01-03 | Tearscience, Inc. | Methods and systems for treating meibomian gland dysfunction using radio-frequency energy |
US7981145B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience Inc. | Treatment of meibomian glands |
US20080114423A1 (en) | 2006-05-15 | 2008-05-15 | Grenon Stephen M | Apparatus for inner eyelid treatment of meibomian gland dysfunction |
US7981095B2 (en) | 2005-07-18 | 2011-07-19 | Tearscience, Inc. | Methods for treating meibomian gland dysfunction employing fluid jet |
US8950405B2 (en) | 2006-05-15 | 2015-02-10 | Tearscience, Inc. | Treatment of obstructive disorders of the eye or eyelid |
US20070060988A1 (en) | 2005-07-18 | 2007-03-15 | Grenon Stephen M | Melting meibomian gland obstructions |
US20090043365A1 (en) | 2005-07-18 | 2009-02-12 | Kolis Scientific, Inc. | Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma |
US20070016256A1 (en) | 2005-07-18 | 2007-01-18 | Korb Donald R | Method and apparatus for treating gland dysfunction |
US8137390B2 (en) | 2006-05-15 | 2012-03-20 | Tearscience, Inc. | System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction |
US8128673B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US8128674B2 (en) | 2006-05-15 | 2012-03-06 | Tearscience, Inc. | System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction |
US9314369B2 (en) | 2006-05-15 | 2016-04-19 | Tearscience, Inc. | System for inner eyelid treatment of meibomian gland dysfunction |
EP2538965B1 (en) | 2010-02-25 | 2017-04-12 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
WO2012048298A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
US9265796B2 (en) * | 2011-07-04 | 2016-02-23 | Mesoblast, Inc. | Methods of treating or preventing rheumatic disease |
CA2840307C (en) | 2011-07-06 | 2021-10-19 | Cell Therapy Limited | Progenitor cells of mesodermal lineage |
FR2983478B1 (en) | 2011-12-01 | 2013-11-15 | Arkema France | PROCESS FOR PREPARING AMINOACID COMPRISING A HYDROFORMYLATION STEP OF UNSATURATED FATTY NITRILE |
CN103505727A (en) * | 2012-06-28 | 2014-01-15 | 中国科学院生物物理研究所 | Application of novel function of CD146 targeted as co-receptor of vascular endothelial growth factor receptor-2 (VEGFR-2) in anti-tumor angiogenesis treatment |
US10842670B2 (en) | 2012-08-22 | 2020-11-24 | Johnson & Johnson Vision Care, Inc. | Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices |
WO2014033184A1 (en) * | 2012-08-28 | 2014-03-06 | Novartis Ag | Use of a vegf antagonist in treating ocular vascular proliferative diseases |
SG10201705061RA (en) * | 2012-12-12 | 2017-07-28 | Mesoblast Inc | Treatment of Diseases of Endothelial Dysfunction and Inflammation |
US9763827B2 (en) | 2013-04-30 | 2017-09-19 | Tear Film Innovations, Inc. | Systems and methods for the treatment of eye conditions |
WO2014179356A1 (en) | 2013-04-30 | 2014-11-06 | Tear Film Innovations Llc | Systems and methods for the treatment of eye conditions |
US9617506B2 (en) | 2013-11-16 | 2017-04-11 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
ES2851386T3 (en) * | 2013-12-18 | 2021-09-06 | Csl Ltd | Wound treatment method |
US11008547B2 (en) | 2014-03-25 | 2021-05-18 | Terumo Bct, Inc. | Passive replacement of media |
CN106715676A (en) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | Scheduled feed |
KR101880790B1 (en) * | 2015-04-07 | 2018-08-16 | 서강대학교산학협력단 | Nanoparticles for genes drug delivery with siRNA for the long -term treatment of retinal disorders and method for preparing the same |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US20170253854A1 (en) * | 2016-03-02 | 2017-09-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of Adipose-Derived Stem Cells for Glaucoma Treatment |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US10974063B2 (en) | 2016-06-30 | 2021-04-13 | Alcon Inc. | Light therapy for eyelash growth |
JP7106788B2 (en) | 2016-07-08 | 2022-07-27 | TAK-Circulator株式会社 | Nucleic acid that suppresses MEX3B gene expression, MEX3B gene expression inhibitor, method for suppressing MEX3B gene expression, and prophylactic or therapeutic agent for diseases caused by MEX3B gene expression |
US11279935B2 (en) | 2016-07-08 | 2022-03-22 | Tak-Circulator Co, Ltd | Method for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 |
CA3028786A1 (en) * | 2016-07-26 | 2018-02-01 | The University Of North Carolina At Chapel Hill | Vector-mediated immune tolerance in the eye |
JP7105195B2 (en) | 2016-11-15 | 2022-07-22 | 株式会社カネカ | Cell population containing mesenchymal stem cells derived from fetal appendages, method for producing the same, and pharmaceutical composition |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
CN110612344B (en) | 2017-03-31 | 2023-09-12 | 泰尔茂比司特公司 | cell expansion |
CN107043699B (en) * | 2017-04-25 | 2023-04-07 | 徐子雁 | Kit for inducing vascularization of mesenchymal stem cells by low-energy laser |
EP3645706A4 (en) * | 2017-06-26 | 2021-04-07 | Amd-Opti, Llc | Autologous stem cell therapies for treatment of eye disease |
US20200368291A1 (en) | 2017-12-28 | 2020-11-26 | Kaneka Corporation | Cell population including adhesive stem cells, production method therefor and pharmaceutical composition |
CA3125309A1 (en) * | 2019-01-03 | 2020-07-09 | Mesoblast International Sarl | Method for improving visual acuity |
US20220233600A1 (en) | 2019-06-14 | 2022-07-28 | Kaneka Corporation | Cell population comprising mesenchymal cells, pharmaceutical composition comprising the same, and method for producing the same |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3089815A (en) | 1951-10-11 | 1963-05-14 | Lieb Hans | Injectable pharmaceutical preparation, and a method of making same |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4983393A (en) | 1987-07-21 | 1991-01-08 | Maximed Corporation | Intra-vaginal device and method for sustained drug release |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5858725A (en) | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
DK0590058T3 (en) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humanized heregulin antibody |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US6824777B1 (en) | 1992-10-09 | 2004-11-30 | Licentia Ltd. | Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
EP0748215B1 (en) | 1994-02-17 | 2003-05-28 | New York Blood Center, Inc. | Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
US6403088B1 (en) | 1995-08-01 | 2002-06-11 | Helsinki University Licensing, Ltd. | Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3) |
US5643192A (en) | 1995-04-06 | 1997-07-01 | Hamilton Civic Hospitals Research Development, Inc. | Autologous fibrin glue and methods for its preparation and use |
US5730977A (en) | 1995-08-21 | 1998-03-24 | Mitsui Toatsu Chemicals, Inc. | Anti-VEGF human monoclonal antibody |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
US20030216335A1 (en) | 2001-11-30 | 2003-11-20 | Jennifer Lockridge | Method and reagent for the modulation of female reproductive diseases and conditions |
US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
DE19638745C2 (en) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR) |
AU733551B2 (en) | 1996-09-25 | 2001-05-17 | Astrazeneca Ab | Qinoline derivatives inhibiting the effect of growth factors such as VEGF |
US6051698A (en) | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US6986890B1 (en) | 1996-11-21 | 2006-01-17 | Kyowa Hakko Kogyo Co., Ltd. | Anti-human VEGF receptor Flt-1 monoclonal antibody |
US6162428A (en) | 1997-02-12 | 2000-12-19 | Layton Bioscience, Inc. | hNT-neuron human neuronal cells to replace ganglion cells |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
AU2299099A (en) | 1998-02-04 | 1999-08-23 | Kyowa Hakko Kogyo Co. Ltd. | Antibodies against human vegf receptor kdr |
EP1555317B1 (en) | 1998-03-20 | 2011-09-28 | Commonwealth Scientific And Industrial Research Organisation | Synthetic genes and genetic constructs comprising the same |
SI1068311T1 (en) | 1998-04-08 | 2011-07-29 | Commw Scient Ind Res Org | Methods and means for obtaining modified phenotypes |
US6284245B1 (en) | 1998-08-25 | 2001-09-04 | Diacrin, Inc. | Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders |
US6383484B1 (en) | 1998-12-21 | 2002-05-07 | Ludwig Institute For Cancer Research | Antibodies to truncated VEGF-D and thereof |
CA2376553A1 (en) | 1999-07-01 | 2001-01-11 | Taisho Pharmaceutical Co., Ltd. | Aminobenzoic acid derivatives |
AU2003901668A0 (en) * | 2003-03-28 | 2003-05-01 | Medvet Science Pty. Ltd. | Non-haemopoietic precursor cells |
AUPQ147799A0 (en) | 1999-07-07 | 1999-07-29 | Medvet Science Pty. Ltd. | Mesenchymal precursor cell |
BR0015203A (en) | 1999-11-05 | 2002-07-16 | Astrazeneca Ab | Quinazoline derivative, process for the preparation of a quinazoline derivative, pharmaceutical composition, use of a compound, and, process for the production of an anti-angiogenic and / or reducing effect on vascular permeability in a warm-blooded animal |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
WO2001066127A1 (en) | 1999-12-21 | 2001-09-13 | Korea Green Cross Corporation | Arginine-rich anti-vascular endothelial growth factor peptides that inhibit growth and metastasis of human tumor cells by blocking angiogenesis |
US7045133B2 (en) | 2000-01-18 | 2006-05-16 | Ludwig Institute For Cancer Research | VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor |
US6733755B2 (en) | 2000-02-04 | 2004-05-11 | Supratek Pharma, Inc. | Ligand for vascular endothelial growth factor receptor |
ATE295365T1 (en) | 2000-02-09 | 2005-05-15 | Novartis Pharma Gmbh | PYRIDINE DERIVATIVES AS ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE INHIBITORS |
US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
AR034118A1 (en) | 2000-02-15 | 2004-02-04 | Sugen Inc | COMPOUNDS OF 2-INDOLINONES REPLACED WITH PROTEINQUINASE INHIBITING PIRROLS; YOUR PHARMACEUTICAL AND INTERMEDIARY SYNTHESIS COMPOSITIONS |
JP2003528632A (en) | 2000-03-31 | 2003-09-30 | インスティティ・パスツール | Peptide inhibiting vascular endothelial growth factor (VEGF) -mediated angiogenesis, polynucleotide encoding the peptide and methods of use |
AU7362301A (en) | 2000-06-22 | 2002-01-02 | Sam L Austin | Bioadhesive compositions and methods of preparation and use |
BR0113056A (en) | 2000-08-09 | 2003-07-08 | Astrazeneca Ab | Compound, process for preparation thereof, pharmaceutical composition, and method for producing an antiangiogenic and / or vascular permeability reducing effect in a warm-blooded animal, and use of a compound |
CA2422934A1 (en) | 2000-10-13 | 2002-04-18 | Institut De Cardiologie De Montreal | Antisense oligonucleotides directed toward mammalian vegf receptor genes and uses thereof |
JP2004517631A (en) | 2001-01-17 | 2004-06-17 | ヨウン メー パク | Method for inhibiting gene expression of vascular endothelial growth factor and erythropoietin by quercetin |
WO2002081520A2 (en) | 2001-04-06 | 2002-10-17 | Maxygen Holdings Ltd. | Single chain dimeric polypeptides derived from the vegf family |
CA2444624A1 (en) | 2001-04-13 | 2002-10-24 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US20050054596A1 (en) | 2001-11-30 | 2005-03-10 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050148530A1 (en) | 2002-02-20 | 2005-07-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US20050222066A1 (en) | 2001-05-18 | 2005-10-06 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7517864B2 (en) | 2001-05-18 | 2009-04-14 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
WO2003070910A2 (en) | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20040209832A1 (en) | 2001-11-30 | 2004-10-21 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US8735153B2 (en) * | 2001-09-24 | 2014-05-27 | Sangamo Biosciences, Inc. | Modulation of stem cells using zinc finger proteins |
US6942655B2 (en) | 2001-11-13 | 2005-09-13 | Minu, Llc | Method to treat age-related macular degeneration |
US20040138163A1 (en) | 2002-05-29 | 2004-07-15 | Mcswiggen James | RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7378246B2 (en) * | 2002-02-28 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for regulating adipogenesis |
US20050100963A1 (en) | 2002-03-01 | 2005-05-12 | Dyax Corporation | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US20040121955A1 (en) | 2002-04-01 | 2004-06-24 | Mulligan-Kehoe Mary Jo | Methods for modulating angiogenesis |
US20040005671A1 (en) | 2002-05-17 | 2004-01-08 | Amrad Operations Pty Ltd. | Immunointeractive molecules |
WO2004033635A2 (en) | 2002-10-04 | 2004-04-22 | Tissuetech, Inc. | Retinal pigment epithelial cell cultures on amniotic membrane and transplantation |
CA2407755A1 (en) * | 2002-10-11 | 2004-04-11 | The Hospital For Sick Children | Inhibition of vegf secretion |
US20060104968A1 (en) * | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
KR20050119671A (en) | 2003-04-03 | 2005-12-21 | 화이자 인코포레이티드 | Dosage forms comprising ag013736 |
US20040198798A1 (en) | 2003-04-07 | 2004-10-07 | Park Jong-Wan | Method for inhibiting tumor angiogenesis and tumor growth |
US20050049309A1 (en) | 2003-07-14 | 2005-03-03 | Lynn Kirkpatrick | Regulation of HIF protein levels via deubiquitination pathway |
AR046510A1 (en) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT |
GB0318423D0 (en) | 2003-08-06 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
US7850959B2 (en) * | 2003-10-10 | 2010-12-14 | Beth Israel Deaconess Medical Center | Methods and compositions for treating conditions involving abnormal angiogenesis |
GB0328021D0 (en) | 2003-12-03 | 2004-01-07 | Inst Of Ophthalmology | Method |
WO2005089224A2 (en) | 2004-03-12 | 2005-09-29 | Alnylam Pharmaceuticals, Inc. | iRNA AGENTS TARGETING VEGF |
EP2290068A3 (en) * | 2004-05-28 | 2012-01-04 | Asuragen, Inc. | Methods and compositions involving microRNA |
US7150970B2 (en) | 2004-08-02 | 2006-12-19 | University Of Iowa Research Foundation | Methods of inhibiting VEGF-C |
WO2006023658A2 (en) * | 2004-08-17 | 2006-03-02 | Prolx Pharmaceuticals Corp. | Method of pre-selecting patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy |
US20060110364A1 (en) | 2004-08-20 | 2006-05-25 | Ludwig Institute For Cancer Research | Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors |
CA2866468C (en) | 2004-09-24 | 2019-09-03 | Mesoblast, Inc. | Generating multipotential expanded mesenchymal precursor cell progeny (memp) from mesenchymal progenitor cells (mpc) and stimulation factor |
US7947267B2 (en) * | 2004-10-08 | 2011-05-24 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
EP1819349A2 (en) * | 2004-11-22 | 2007-08-22 | King Pharmaceuticals Research and Development Inc. | Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists |
RU2418856C2 (en) * | 2005-02-24 | 2011-05-20 | Дзе Скриппс Рисерч Инститьют | Isolated populations of myeloid-like cells of bone marrow and methods of treatment with them |
US20070231306A1 (en) * | 2005-02-24 | 2007-10-04 | The Scripps Research Institute | Isolated myeloid-like cell populations and methods of treatment therewith |
CA2604493C (en) | 2005-04-12 | 2015-12-22 | Angioblast Systems, Inc. | Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase |
US20060234941A1 (en) | 2005-04-15 | 2006-10-19 | The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis |
WO2007013704A1 (en) | 2005-07-27 | 2007-02-01 | Juseong College Industry Academy Cooperation Group | Recombinant adeno-associated virus comprising antisense cdnas of vegf-a, vegf-b and vegf-c and gene therapeutic agent specific to large intestine cancer, bladder cancer and/or lung cancer comprising the same |
EP1954272A2 (en) | 2005-10-31 | 2008-08-13 | Bayer Pharmaceuticals Corporation | Treatment of cancer with sorafenib |
GB0523810D0 (en) | 2005-11-23 | 2006-01-04 | Astrazeneca Ab | Pharmaceutical compositions |
CN100371444C (en) | 2005-12-12 | 2008-02-27 | 清华大学深圳研究生院 | VEGF expression-inhibiting siRNA and application thereof |
CN100374573C (en) | 2006-04-14 | 2008-03-12 | 中国医学科学院医药生物技术研究所 | Carrier PCD-VEGF able to stable express VEGF shRNA |
US20080089868A1 (en) | 2006-04-27 | 2008-04-17 | The Research Foundation Of State University Of New York | Retinal stem cell compositions and methods for preparing and using same |
WO2007130060A2 (en) | 2006-05-03 | 2007-11-15 | Schepens Eye Research | Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues |
WO2007136673A2 (en) * | 2006-05-19 | 2007-11-29 | Medistem Laboratories, Inc. | Treatment of disc degenerative disease and compositions for same |
WO2007140534A1 (en) | 2006-06-08 | 2007-12-13 | Csl Limited | Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling |
KR100787131B1 (en) | 2006-07-04 | 2007-12-21 | 한국생명공학연구원 | Compounds that inhibit hif-1 activity the method for preparation thereof and the pharmaceutical composition containing them as an effective component |
DK2046349T3 (en) * | 2006-07-12 | 2015-12-21 | Mesoblast Inc | TREATMENT OF EXCESSIVE NEOVASCULARIZATION |
CA2658972C (en) * | 2006-07-31 | 2019-11-26 | Vascular Biogenics Ltd. | Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia |
WO2008031835A2 (en) | 2006-09-13 | 2008-03-20 | Novartis Ag | Method of treating autoimmune diseases using vegf-pathway inhibitors |
WO2008045576A2 (en) | 2006-10-12 | 2008-04-17 | Yijia Liu | Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases |
JP5721949B2 (en) * | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | Compound drug |
EP2089059A2 (en) * | 2006-11-10 | 2009-08-19 | Genentech, Inc. | Method for treating age-related macular degeneration |
WO2008098299A1 (en) * | 2007-02-14 | 2008-08-21 | Opto Global Holdings Pty Ltd | Methods and systems of treating age-related macular degeneration |
US8983570B2 (en) * | 2007-03-27 | 2015-03-17 | Cardiovascular Biotherapeutics, Inc. | Therapeutic angiogenesis for treatment of the spine |
US7867724B2 (en) * | 2007-11-05 | 2011-01-11 | California Institute Of Technology | Compositions and method of treating hypoxia-associated diseases |
WO2009114623A2 (en) * | 2008-03-11 | 2009-09-17 | University Of North Carolina At Chapel Hill | Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same |
US8691866B2 (en) * | 2008-12-10 | 2014-04-08 | The General Hospital Corporation | HIF inhibitors and use thereof |
JP2013540420A (en) * | 2010-07-07 | 2013-11-07 | テュビタク−テュルキイェ・ビリムセル・ヴェ・テクノロジク・アラスティルマ・クムル | Recombinant antibody structure that binds to vascular endothelial growth factor 2 (VEGFR-2 / KDR) and blocks its activity |
-
2009
- 2009-06-29 AU AU2009269149A patent/AU2009269149B2/en not_active Ceased
- 2009-06-29 SG SG10201510586PA patent/SG10201510586PA/en unknown
- 2009-06-29 EP EP09794792A patent/EP2294184A4/en not_active Withdrawn
- 2009-06-29 JP JP2011516339A patent/JP2011526892A/en not_active Withdrawn
- 2009-06-29 KR KR1020117002350A patent/KR20110036101A/en not_active Application Discontinuation
- 2009-06-29 WO PCT/US2009/003902 patent/WO2010005527A1/en active Application Filing
- 2009-06-29 CN CN2009801249790A patent/CN102076844B/en not_active Expired - Fee Related
- 2009-06-29 US US13/002,229 patent/US20110200612A1/en not_active Abandoned
- 2009-06-29 CA CA2729303A patent/CA2729303A1/en not_active Abandoned
-
2014
- 2014-07-04 JP JP2014138345A patent/JP2015038059A/en active Pending
-
2016
- 2016-06-14 AU AU2016203973A patent/AU2016203973A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102076844B (en) | 2013-08-07 |
EP2294184A4 (en) | 2013-03-06 |
AU2009269149B2 (en) | 2016-03-17 |
JP2011526892A (en) | 2011-10-20 |
AU2009269149A1 (en) | 2010-01-14 |
AU2016203973A1 (en) | 2016-06-30 |
CN102076844A (en) | 2011-05-25 |
US20110200612A1 (en) | 2011-08-18 |
WO2010005527A1 (en) | 2010-01-14 |
KR20110036101A (en) | 2011-04-06 |
JP2015038059A (en) | 2015-02-26 |
EP2294184A1 (en) | 2011-03-16 |
CA2729303A1 (en) | 2010-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201510586PA (en) | Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy | |
IL242268A0 (en) | Combinations and modes of administration of therapeutic agents and combination therapy | |
ZA201106268B (en) | Toll-like receptor modulators and treatment of diseases | |
HK1201046A1 (en) | Methods of treating ophthalmic diseases | |
IL207014A0 (en) | Enhanced delivery of a therapeutic to ocular tissues through iontophoresis | |
IL229786A (en) | Use of inhibitors for preparation of medicaments for treating ocular edema, neovascularization and related diseases | |
ZA201106730B (en) | Methods of treatment using combination therapy | |
EP2182983A4 (en) | Treatment of amyloidogenic diseases | |
HK1173654A1 (en) | Therapeutic compounds and related methods of use | |
EP2046349A4 (en) | Treatment of excessive neovascularization | |
ZA200906165B (en) | Treatment and prevention of neurodegenerative diseases using gene therapy | |
HK1243436A1 (en) | Therapeutic use of specific ligand in msrv associated diseases | |
EP2624821A4 (en) | Combination therapy for the treatment of depression and other non-infectious diseases | |
EP2710017A4 (en) | Macrocycllc therapeutic agents and methods of treatment | |
IL214291A (en) | Use of deferiprone for preparation of a medicament for treatment and prevention of iron-related eye disorders | |
AU2008903349A0 (en) | Treatment of eye diseases and excessive neovascularization using combined therapy | |
GB201108289D0 (en) | Therapeutic garment and method of providing therapy using the same | |
GB0801511D0 (en) | The treatment of ophthalmic diseases | |
IL231052B (en) | Bacteriochlorophyll photosensitizers for treatment of eye diseases and disorders | |
GB0901727D0 (en) | The treatment of ophthalmic diseases | |
GB0724970D0 (en) | Treatment and prevention of nuerodegenerative diseases | |
ZA200906883B (en) | Methods of treating ophthalmic diseases | |
GB0700755D0 (en) | The Treatment of ophthalmic diseases | |
GB0920200D0 (en) | Therapeutic vaccine for treatment of type 2-diabetes and impaired glucose tolerance | |
GB0920424D0 (en) | Therapeutic vaccine for treatment of type 2-diabetes and impaired glucose tolerance |